Delving into the Latest Updates on Normal Human Immunoglobulin (CSL Behring) with Synapse

A Phase 3, Prospective, Open-label, Multicenter, Single-arm Study to Investigate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Subjects With Secondary Immune Deficiency Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (CAR T-cell) and T-cell redirecting therapies (such as T-cell engager bispecific antibody [TCE BsAb] therapy). The primary objective is to demonstrate that true annualized rate of serious bacterial infection (SBIs) is less than (<) 1.0.
This study includes two cohorts:
1. Loading Cohort: Participants with serum immunoglobulin G (IgG) < 500 milligrams per deciliter (mg/dL) at Screening, with or without ongoing immunoglobulin replacement therapy (IgRT) during Screening, who must have received five doses of IgPro20 during the Initial Treatment Period.
2. Maintenance-only Cohort: Participants with serum IgG greater than or equal to (≥) 500 mg/dL and ongoing IgRT at Screening, who must have received one dose of IgPro20 during the Initial Treatment Period.

Start Date24 Jul 2026

Sponsor / Collaborator

CSL Behring LLC

CTIS2025-522756-97-00

/ Not yet recruitingPhase 2IIT

Randomized Open Label Trial Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg, Privigen) as Add-on to SoC Versus SoC Alone for Coronavirus Disease 2019 (COVID-19) in Patients with Severely Impaired B-cell Function

Start Date02 Jan 2026

Sponsor / Collaborator-

NCT07076446

/ CompletedPhase 4

An Open-label, Multicenter Study to Assess the Pharmacokinetics, Safety, and Tolerability of Immune Globulin Subcutaneous (Human) IgPro20 in IG Treatment-naïve Subjects With Primary Immunodeficiency

This is an open-label, multicenter, phase 4 study in IG treatment-naïve participants with PID, conducted in the United States (US), to assess the PK, safety, and tolerability of IgPro20. The primary objective of this study is to characterize the PK of IgPro20 and to assess the safety and tolerability of IgPro20 in IG treatment-naïve participants with PID who are aged greater than or equal to (>=) 18 years.

Start Date15 Jul 2025

Sponsor / Collaborator

CSL Behring LLC

100 Clinical Results associated with Normal Human Immunoglobulin (CSL Behring)

Login to view more data

100 Translational Medicine associated with Normal Human Immunoglobulin (CSL Behring)

Login to view more data

100 Patents (Medical) associated with Normal Human Immunoglobulin (CSL Behring)

Login to view more data

1,047

Literatures (Medical) associated with Normal Human Immunoglobulin (CSL Behring)

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

The economic value of self-administered subcutaneous immunoglobulin G (SCIg) in Canada: a scoping review

Review

Author: Mac, Stephen ; Manuel, Megan ; Fakhraei, Romina ; Cheung, Antoinette ; Giangregorio, Aidan ; Betschel, Stephen D.

BACKGROUND:

Subcutaneous immunoglobulin (SCIg) is a treatment available in Canada for patients requiring antibody replacement. While standard-of-care involves in-hospital intravenous Ig (IVIg) treatment, SCIg allows for home-based administration and fewer clinic visits, representing a common treatment choice. This study summarized the economic value of SCIg vs. IVIg treatment in Canada.

METHODS:

A scoping review was conducted using Medline and Embase, supplemented by grey literature searches. Eligibility criteria were clinical studies and economic evaluations reporting cost and healthcare resource use (HCRU) outcomes of SCIg or IVIg treatment in Canada (any condition). Types and estimates of costs (Canadian dollars [CAN$]), cost-effectiveness, and HCRU were summarized. Estimates from economic models were inflated to 2025 CAN$ and standardized as cost savings per-patient per-year.

RESULTS:

From 824 database abstracts and 10 grey literature citations, 21 eligible articles were included; articles without Canadian economic data for IVIg or SCIg were excluded. Lower costs and HCRU were reported for SCIg vs. IVIg (n=7 studies), where reductions in total cost ranged from $1,795 to $5,386/patient/year (uninflated). Staffing time and lost productivity were also lower; SCIg required 45-57 fewer nursing hours/patient/year, and 51-82 fewer parental hours/patient/year. Lower costs with SCIg were driven by reduced infusion materials, staff time, transportation to clinics, and lost productivity. Across economic models, annual cost savings were substantial after switching patients from IVIg to SCIg; post-inflation estimates averaged from $1,947 to $7,152 per patient. In a cost-utility analysis, SCIg was less costly while providing greater quality-adjusted life-years than hospital-based IVIg, even when hospital/staff costs for IVIg were lowered by 50%.

CONCLUSION:

SCIg represents an important treatment option both for alleviating burden to the Canadian healthcare system and for patients. Substantial cost savings were estimated by switching from IVIg to SCIg. These findings provide evidence to support healthcare decision-making from an economic perspective.

01 Jul 2026·Journal of Pediatric Nursing-Nursing Care of Children & Families

Quality of life and care burden in mothers of primary immunodeficient children receiving SCIG and IVIG: A descriptive correlational study

Article

Author: Dönmez, Hatice ; Geçkil, Emine ; Alan, Havva Bozkurt ; Köse, Semra

PURPOSE:

This study aimed to determine the Pediatric Quality of Life with PID according to their method of Ig administration, the care burden of their mothers, and the relationship between these two factors.

DESIGN AND METHODS:

This descriptive and correlational study was conducted with children aged 2-18 years diagnosed with primary immunodeficiency and their mothers at a university hospital in Konya (n = 98). Data were collected using the "Child and Mother Diagnosis Form," the "Pediatric Quality of Life Inventory (PEDSQL)," and the "Caregiving Burden Scale."

RESULTS:

According to both parent and child reports, there was no significant difference in Pediatric Quality of Life scores between IVIG and SCIG groups SCIG (p > 0.05). Similarly, maternal caregiving burden did not differ significantly by IG administration method or age range (p > 0.05). Notably, a strong negative correlation was identified between children's quality of life and maternal care burden in mother-reported outcomes (r = -0.710, p = 0.000). However, this relationship was not statistically significant in child-reported outcomes.

CONCLUSION:

In conclusion, the method of Ig administration (IVIG vs. SCIG) does not appear to influence pediatric quality of life or maternal caregiving burden. However, a significant link exists between these two variables: as the child's quality of life decreases, the mother's caregiving burden increases, especially according to parental reports.

PRACTICE IMPLICATIONS:

Nursing interventions aimed at improving parental skills can be incorporated into parental skill-based treatments, such as SCIG, to reduce maternal care burden.

01 Jun 2026·CLINICAL PHARMACOKINETICS

Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review

Review

Author: Preijers, T ; van Tilburg, S J ; Koch, B C P ; Dalm, V A S H ; Jacobs, B C ; van der Zeeuw, S L ; Crombag, M B S

BACKGROUND AND OBJECTIVE:

Intravenous and/or subcutaneous immunoglobulins (IVIg/SCIg) are used as immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiencies (PID/SID) and as immunomodulatory therapy in immune-mediated diseases. Despite empiric immunoglobulin G (IgG) target concentrations in PID, dosing remains variable and suboptimal, particularly in immune-mediated diseases lacking clear IgG target concentrations. Population pharmacokinetic (popPK) and pharmacodynamic (PD) modelling may clarify interindividual variability and support individualised dosing. Recent developments extend beyond PID, emphasising the importance of integrated PK-PD approaches to optimise IgG therapy. This review aimed to provide a comprehensive overview of popPK(-PD) models describing polyclonal IgG therapy, and to emphasise the added value of PK-PD in understanding drug behaviour.

METHODS:

A systematic literature search was conducted in Embase, MEDLINE, and Web of Science from inception to August 2025. Studies describing popPK(-PD) models for exogenous polyclonal IVIg and/or SCIg administration in humans were included.

RESULTS:

In total, 14 studies were included. While most popPK models focus on PID (N = 10), an increasing number address immune-mediated diseases. Immunoglobulin G pharmacokinetics are typically described using two-compartment models with first-order kinetics, using body weight (BW) as a common covariate for clearance and volume of distribution. Endogenous IgG is often incorporated as a fixed PK parameter; however, this may not adequately capture interindividual variability and potential effects of Ig treatment on IgG concentrations. Two popPK-PD models link IgG concentrations to clinical outcomes in immune-mediated diseases. In contrast, such models are currently lacking for PID. Simulations showed consistent predicted IgG concentrations following SCIg in PID, while IVIg models in PID showed more variability.

CONCLUSIONS:

PopPK models have advanced understanding of IgG PK and its variability between patients and treatment regimens. These models provide a powerful framework to support individualised dosing strategies, thereby potentially reducing reliance on empirical, trial-and-error dosing approaches. However, clear target concentrations are lacking and must be established for individual patients. Models may be further optimised by incorporating essential Neonatal Fc receptor (FcRn) mechanisms using physiology-based pharmacokinetic (PBPK) or semi-mechanistic models. In conclusion, current models are useful to predict IgG concentrations across diseases during Ig treatment; however, a clearer relationship with PD is required. Hence, these findings can guide clinical trial design for tailored dosing regimens.

25

News (Medical) associated with Normal Human Immunoglobulin (CSL Behring)

12 Jun 2026

·pmlive.com

CSL’s Privigen approved as measles treatment by European Commission

CSL has been given marketing authorisation from the European Commission for Privigen, a human immunoglobulin therapy indicated for pre- and post-exposure prophylaxis to prevent and reduce the risk of measles where vaccination is contraindicated or not recommended. Privigen is a human immunoglobulin therapy that can be used to prevent and reduce the risk of measles where vaccination is contraindicated or not recommended. Cases of measles have been rising in Europe since 2023. Health authorities across Europe, including the European Centre for Disease Prevention and Control, reported a sharp increase in measles cases in 2024. In 2025, case numbers remained elevated, with reported infections approximately twice as high as in 2023. Emmanuelle Lecomte Brisset, Head of Global Regulatory Affairs and Safety at CSL, said: “While vaccination remains the most effective way to prevent measles, outbreaks across Europe highlight the urgent need for additional tools to protect those at risk. This approval ensures clinicians have access to an immunoglobulin option where passive protection may be considered.” Privigen has been authorised for use in susceptible high-risk individuals, including immunocompromised patients, pregnant women without evidence of immunity, and infants or other vulnerable contacts with high unmet needs. It has a well-established safety profile based on clinical use and long-term real-world experience with immunoglobulin therapies. Immunoglobulin therapy works by providing concentrated antibodies that can neutralise the measles virus after exposure and may provide passive antibody protection following exposure. This makes immunoglobulin therapy a potential option for individuals who cannot rely on vaccination or require prompt prophylactic support following exposure. European approval is based on strong clinical and real-world evidence supporting the safety and efficacy of Privigen for the approved use in preventing measles and protecting high-risk patients.

Drug ApprovalImmunotherapy

04 May 2026

·allsci.com

Takeda’s Tak-881 meets primary endpoint in Phase II/III primary immunodeficiency disease trial

Takeda (TSE:4502/NYSE:TAK) reported that TAK-881, an investigational immune globulin subcutaneous 20% formulation facilitated by recombinant human hyaluronidase, met its primary endpoint in a pivotal Phase II/III trial in primary immunodeficiency disease, demonstrating pharmacokinetic comparability to Hyqvia (immune globulin infusion 10% with recombinant human hyaluronidase) while delivering the equivalent immunoglobulin dose in half the infusion volume. The TAK-881-3001 trial is a pivotal Phase II/III, open-label, randomized crossover study evaluating TAK-881 against Hyqvia in adults and pediatric patients aged two years and older with PID who had previously received immunoglobulin therapy. TAK-881-3001 met its primary endpoint of pharmacokinetic equivalence, with a geometric mean ratio of 99.67% for AUC0-tau,ss — the area under the IgG concentration-time curve over one dosing interval at steady state — with a 90% confidence interval of 95.10% to 104.46%, falling within the prespecified equivalence bounds. Secondary endpoints showed comparable infection rates and immune protection, with protective IgG levels maintained throughout the study. The safety and tolerability profiles were also comparable to Hyqvia, with no new safety signals identified. TAK-881 is composed of a 20% immunoglobulin solution co-administered with Halozyme’s rHuPH20 enzyme, which transiently degrades hyaluronan in the subcutaneous extracellular matrix, increasing tissue permeability and enabling larger infusion volumes at a single site. Hyqvia, the established comparator and current Takeda-marketed product, uses the same delivery mechanism but at a 10% immunoglobulin concentration. The doubling of concentration in TAK-881 is what allows the same IgG dose to be delivered in half the volume, with the potential to shorten infusion duration while preserving the up to once-monthly dosing schedule — every three or four weeks for PID — that distinguishes facilitated subcutaneous immunoglobulin from conventional weekly or biweekly subcutaneous regimens. The primary immunodeficiency disease treatment landscape is crowded with approved options spanning intravenous and subcutaneous formulations from CSL Behring, Grifols, Octapharma, and Takeda itself, but the facilitated subcutaneous segment remains narrow. Hyqvia, approved in the US for adults and children aged two and older with PID, is the only currently approved fSCIG product, and TAK-881 is being developed explicitly as a next-generation candidate within that same mechanistic class. Cross-trial comparisons are limited by differences in patient populations, study designs, and endpoints, but within Takeda’s own portfolio, TAK-881 would sit above both Hyqvia and the conventional SCIG product Cuvitru (immune globulin subcutaneous 20%) in terms of per-infusion volume efficiency. The trial enrolled participants across two distinct arms. Adults and patients aged 16 and older were randomized in an open-label crossover design, receiving TAK-881 followed by Hyqvia or the reverse sequence, with the same dose and dosing interval maintained for up to 51 weeks. Pediatric patients aged two to under 16 were enrolled in a separate open-label single-arm segment and treated with TAK-881 only for up to 27 weeks. This design reflects a pragmatic approach to a population where crossover against an active comparator in younger children raises both ethical and logistical complications, though the absence of a direct pediatric comparison with Hyqvia means the pediatric dataset will be interpreted primarily against historical benchmarks rather than concurrent controls. For patients requiring lifelong immunoglobulin replacement, the practical dimensions of therapy — infusion duration, number of needle insertions, and dosing frequency — carry weight alongside clinical outcomes. Conventional subcutaneous immunoglobulins such as Hizentra (immune globulin subcutaneous 20%) from CSL Behring or Xembify (immune globulin subcutaneous 20%) from Grifols require multiple infusion sites per session due to per-site volume constraints, typically necessitating weekly administration. Hyqvia addressed part of that burden by enabling single-site, once-monthly infusion, but sessions can still extend to several hours depending on dose. A 20% concentration formulation with the same hyaluronidase-facilitated platform could reduce that session time, though Takeda has not yet disclosed specific infusion duration data from TAK-881-3001. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Clinical ResultDrug ApprovalImmunotherapy

13 Mar 2026

·www.biospace.com

KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”) , a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that its Freedom60® Infusion Pump, including adapter for use with 50 mL prefilled syringes, has achieved certification under the European Union Medical Devices Regulation (EU MDR 2017/745), enabling commercialization across the European Union. The Freedom60 Infusion Pump is designed to support dosing with 50 ml prefilled syringes, while the FreedomEDGE® Infusion System provides a compatible option for 20 mL prefilled syringe formats. Together, these systems offer clinicians and patients flexibility across dosing regimens while maintaining a consistent, intuitive user experience. EU MDR certification of both the Freedom60 and FreedomEDGE Infusion Pumps expands access to a system designed to support the growing use of prefilled syringes in subcutaneous immunoglobulin (SCIg) therapy and simplify the home infusion experience for patients. The increasing availability of prefilled syringe formats represents an important step forward in the evolution of SCIg therapy. Published studies have shown that prefilled presentations can: Reduce preparation and administration step vs vials 1 Minimize medication handling 1 Decrease overall treatment burden 2 Improve patient confidence and independence with home therapy 3 “EU MDR certification for the Freedom60 Infusion Pump marks an important step in expanding access to simpler, more patient-focused SCIg delivery across Europe,” said Linda Tharby, President and Chief Executive Officer of KORU Medical Systems. “As prefilled syringes become more widely adopted, patients are looking for solutions that reduce complexity and fit more easily into their daily routines. Our Freedom60 and FreedomEDGE systems are designed to meet that need - helping streamline therapy while maintaining the reliability that clinicians and patients expect.” About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60 ® and FreedomEDGE ® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Actual results may differ materially from these statements due to potential risks and uncertainties such as those included under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, which is on the SEC and available on our website at and on the SEC website at . All information provided in this release and in the attachments is as of March 13, 2026. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. CSL Behring LLC. Hizentra® PI 10 g Prefilled Syringe Leave-Behind (Document No. USA-HPI-0042 ; USA-HPI-0042-DEC23). Approved Dec 21, 2023 . Mallick R, Solomon G, Bassett P, Zhang X, Patel P, Lepeshkina O. Subcutaneous immunoglobulin replacement therapy in patients with immunodeficiencies – impact of drug packaging and administration method on patient reported outcomes. BMC Immunology. 2024;25:18. doi:10.1186/s12865-024-00608-0 Pandya D, Tavanti M, Hubsch A, Panaite A, Murphy E, Ramakrishna B, Mielke O. Successful simulation of infusion pump use for IgPro20 prefilled syringes. Poster 116. Presented at the Immunoglobulin National Society (IgNS) 13th National Conference; Oct 17–20, 2024; Washington, DC, USA. CSL Behring Medical Affairs. Contacts Investor Contact: Louisa Smith investor@korumedical.com

100 Deals associated with Normal Human Immunoglobulin (CSL Behring)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Measles	European Union	CSL Behring GmbH	09 Jun 2026
Measles	Iceland	CSL Behring GmbH	09 Jun 2026
Measles	Liechtenstein	CSL Behring GmbH	09 Jun 2026
Measles	Norway	CSL Behring GmbH	09 Jun 2026
Secondary immunodeficiencies	European Union	CSL Behring GmbH	14 Apr 2011
Secondary immunodeficiencies	Iceland	CSL Behring GmbH	14 Apr 2011
Secondary immunodeficiencies	Liechtenstein	CSL Behring GmbH	14 Apr 2011
Secondary immunodeficiencies	Norway	CSL Behring GmbH	14 Apr 2011
Acquired Immunodeficiency Syndrome	European Union	CSL Behring GmbH	24 Apr 2008
Acquired Immunodeficiency Syndrome	Iceland	CSL Behring GmbH	24 Apr 2008
Acquired Immunodeficiency Syndrome	Liechtenstein	CSL Behring GmbH	24 Apr 2008
Acquired Immunodeficiency Syndrome	Norway	CSL Behring GmbH	24 Apr 2008
Agammaglobulinemia	European Union	CSL Behring GmbH	24 Apr 2008
Agammaglobulinemia	Iceland	CSL Behring GmbH	24 Apr 2008
Agammaglobulinemia	Liechtenstein	CSL Behring GmbH	24 Apr 2008
Agammaglobulinemia	Norway	CSL Behring GmbH	24 Apr 2008
Bacterial Infections	European Union	CSL Behring GmbH	24 Apr 2008
Bacterial Infections	Iceland	CSL Behring GmbH	24 Apr 2008
Bacterial Infections	Liechtenstein	CSL Behring GmbH	24 Apr 2008
Bacterial Infections	Norway	CSL Behring GmbH	24 Apr 2008

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematologic Neoplasms	Phase 3	United States	CSL Behring LLC	24 Jul 2026
Hematologic Neoplasms	Phase 3	Belgium	CSL Behring LLC	24 Jul 2026
Hematologic Neoplasms	Phase 3	Canada	CSL Behring LLC	24 Jul 2026
Hematologic Neoplasms	Phase 3	Czechia	CSL Behring LLC	24 Jul 2026
Hematologic Neoplasms	Phase 3	Denmark	CSL Behring LLC	24 Jul 2026
Hematologic Neoplasms	Phase 3	France	CSL Behring LLC	24 Jul 2026
Hematologic Neoplasms	Phase 3	Germany	CSL Behring LLC	24 Jul 2026
Hematologic Neoplasms	Phase 3	Italy	CSL Behring LLC	24 Jul 2026
Hematologic Neoplasms	Phase 3	Poland	CSL Behring LLC	24 Jul 2026
Hematologic Neoplasms	Phase 3	Spain	CSL Behring LLC	24 Jul 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06524739 (CTgov)	Phase 3	Postural Orthostatic Tachycardia Syndrome \| Post Acute COVID 19 Syndrome	16	IgPro20 (IgPro20 (Double-blind Period))	qxizbjkiql = nukzkudsqr ambxrxdxjx (nhorxjvung, uphfcxixab - jtuvwprcau) View more	-	13 Apr 2026
				Placebo (Placebo (Double-blind Period))	qxizbjkiql = rivmiuebma ambxrxdxjx (nhorxjvung, drdkdbonum - krxcshbcdx) View more
NCT04044690 (RECLAIIM, CTgov)	Phase 3	Dermatomyositis	134	human immunoglobulin G (IgPro20)	gonpsponaa = bssgzworle iyuludoxpi (jtotedsdnb, wbdihjiccg - fdhkvqjosp) View more	-	09 Dec 2025
				Placebo (Placebo)	gonpsponaa = iwcfwmdpgc iyuludoxpi (jtotedsdnb, awiqhlbhhv - lfmrdxlotd) View more
ASH2025	Not Applicable	B-Cell Lymphoma	56	Lisocabtagene maraleucel (Low serum IgG at apheresis (<700 mg/dL))	ocrdghmhcc(dwzzlmbfwj) = hzqhdjmsja qpksqaroqy (kapjbzsfsv ) View more	Positive	06 Dec 2025
				Lisocabtagene maraleucel (High serum IgG at apheresis (≥700 mg/dL))	ocrdghmhcc(dwzzlmbfwj) = cytiwrjekg qpksqaroqy (kapjbzsfsv ) View more
NCT04137224 (Pubmed \| Rheumatology (Oxford))	Phase 2	Scleroderma, Diffuse	-	IgPro20	ifapkhhzvj(ydrypmyaot) = 76.1% uyjlipfuvc (yzkpxkevnu )	Positive	05 Feb 2025
				IgPro10
NCT02465359 (SCIG, CTgov)	Not Applicable	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	15	Immune Globulin Subcutaneous (Human)	iddpkspgaw(yiveikhofc) = tptqromiio ksnqrcqyje (dowdxqpiiq, gtjbouzqch - vommgqcoen) View more	-	08 Oct 2024
NCT03919773 (iSTAND, CTgov)	Phase 1/2	Postural Orthostatic Tachycardia Syndrome	30	IVIG (Treatment IVIG Arm)	ufmejdjilh(zoqlycvwbb) = bifxflwcbh ffojighqor (dbxiyiqxtc, gkgmgixsau - yeehxcdsqd) View more	-	19 Sep 2024
				Albumin (Treatment Albumin Arm)	ufmejdjilh(zoqlycvwbb) = cpltgiufsv ffojighqor (dbxiyiqxtc, xblysuouug - dzpmabonos) View more
NCT04137224 (CTgov)	Phase 2	Scleroderma, Diffuse	27	IgPro20 (Sequence A: IgPro20)	pqsoooyjcn = zjkxjlildp hnovykvsrd (fjqdtrmaim, tnypzcrchz - fixxofslmz) View more	-	05 Feb 2024
				IgPro20 (Sequence B: IgPro20)	pqsoooyjcn = jpnvpzxsgb hnovykvsrd (fjqdtrmaim, uaoyacbgiq - fwiopttfto) View more
NCT03401268 (Pubmed \| Hematol Oncol Stem Cell Ther) Manual	Not Applicable	Hematopoietic stem cell transplantation	20	Subcutaneous immunoglobulin	oezjutclch(vlerbilnur) = wlwfbyamoj psnizmvjuk (xpmnpkaemc ) View more	Positive	01 Dec 2021
NCT04044690 (Pubmed \| Rheumatology (Oxford)) Manual	Phase 3	Myositis First line	20	Privigen	buuiatknss(kcsvhxbyhn) = wdfychsgsk clprdjcini (sohdsnqnmu ) View more	Positive	06 Apr 2021
NCT03033745 (HILO, Pubmed \| J Clin Immunol)	Phase 4	Primary Immunodeficiency Diseases	33	Subcutaneous IgPro20 (Pump-Assisted Volume Cohort)	gawjighyou(blrarismsv) = jainxdxzfp xcoctoqrle (mxkogmxflt ) View more	-	01 Feb 2021
				Subcutaneous IgPro20 (Pump-Assisted Flow Rate Cohort)	gawjighyou(blrarismsv) = esfitiqkom xcoctoqrle (mxkogmxflt ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data